321 related articles for article (PubMed ID: 29869646)
1. Eravacycline for the treatment of patients with bacterial infections.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2018 Apr; 54(4):245-254. PubMed ID: 29869646
[TBL] [Abstract][Full Text] [Related]
2. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Popejoy MW; Long J; Huntington JA
BMC Infect Dis; 2017 May; 17(1):316. PubMed ID: 28464828
[TBL] [Abstract][Full Text] [Related]
3. Eravacycline for the treatment of intra-abdominal infections.
Bassetti M; Righi E
Expert Opin Investig Drugs; 2014 Nov; 23(11):1575-84. PubMed ID: 25251475
[TBL] [Abstract][Full Text] [Related]
4. Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial.
Solomkin J; Evans D; Slepavicius A; Lee P; Marsh A; Tsai L; Sutcliffe JA; Horn P
JAMA Surg; 2017 Mar; 152(3):224-232. PubMed ID: 27851857
[TBL] [Abstract][Full Text] [Related]
5. IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections.
Solomkin JS; Gardovskis J; Lawrence K; Montravers P; Sway A; Evans D; Tsai L
Clin Infect Dis; 2019 Aug; 69(6):921-929. PubMed ID: 30561562
[TBL] [Abstract][Full Text] [Related]
6. Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.
Zhanel GG; Cheung D; Adam H; Zelenitsky S; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty A; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2016 Apr; 76(5):567-88. PubMed ID: 26863149
[TBL] [Abstract][Full Text] [Related]
7. Eravacycline, a newly approved fluorocycline.
Lee YR; Burton CE
Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1787-1794. PubMed ID: 31175478
[TBL] [Abstract][Full Text] [Related]
8. Imipenem/cilastatin sodium/relebactam fixed combination to treat urinary infections and complicated intra-abdominal bacterial infections.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2020 Apr; 56(4):241-255. PubMed ID: 32309820
[TBL] [Abstract][Full Text] [Related]
9. Eravacycline for the treatment of complicated intra-abdominal infections.
Montravers P; Zappella N; Tran-Dinh A
Expert Rev Anti Infect Ther; 2019 Nov; 17(11):851-863. PubMed ID: 31622119
[No Abstract] [Full Text] [Related]
10. Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance.
Solomkin JS; Sway A; Lawrence K; Olesky M; Izmailyan S; Tsai L
Future Microbiol; 2019 Oct; 14():1293-1308. PubMed ID: 31570004
[No Abstract] [Full Text] [Related]
11. Eravacycline: A Review in Complicated Intra-Abdominal Infections.
Scott LJ
Drugs; 2019 Feb; 79(3):315-324. PubMed ID: 30783960
[TBL] [Abstract][Full Text] [Related]
12. Eravacycline (Xerava)--an IV tetracycline for complicated intra-abdominal infections.
Med Lett Drugs Ther; 2019 Apr; 61(1570):61-63. PubMed ID: 31169809
[No Abstract] [Full Text] [Related]
13. Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline.
McCarthy MW
Clin Pharmacokinet; 2019 Sep; 58(9):1149-1153. PubMed ID: 31049869
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Eravacycline: A Novel Fluorocycline.
Alosaimy S; Abdul-Mutakabbir JC; Kebriaei R; Jorgensen SCJ; Rybak MJ
Pharmacotherapy; 2020 Mar; 40(3):221-238. PubMed ID: 31944332
[TBL] [Abstract][Full Text] [Related]
15. Novel β-lactam/β-lactamase inhibitors versus alternative antibiotics for the treatment of complicated intra-abdominal infection and complicated urinary tract infection: a meta-analysis of randomized controlled trials.
Chen M; Zhang M; Huang P; Lin Q; Sun C; Zeng H; Deng Y
Expert Rev Anti Infect Ther; 2018 Feb; 16(2):111-120. PubMed ID: 29343141
[TBL] [Abstract][Full Text] [Related]
16. New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance.
Syue LS; Chen YH; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2016 Apr; 47(4):250-8. PubMed ID: 27005457
[TBL] [Abstract][Full Text] [Related]
17. Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options.
Golan Y
BMC Infect Dis; 2015 Aug; 15():313. PubMed ID: 26243291
[TBL] [Abstract][Full Text] [Related]
18. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections.
Solomkin JS; Ramesh MK; Cesnauskas G; Novikovs N; Stefanova P; Sutcliffe JA; Walpole SM; Horn PT
Antimicrob Agents Chemother; 2014; 58(4):1847-54. PubMed ID: 24342651
[TBL] [Abstract][Full Text] [Related]
19. New and Emerging Antibiotics for Complicated Intra-Abdominal Infections.
Durand CR; Alsharhan M; Willett KC
Am J Ther; 2017; 24(6):e763-e769. PubMed ID: 26796653
[TBL] [Abstract][Full Text] [Related]
20. Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.
Scott LJ
Drugs; 2016 Feb; 76(2):231-42. PubMed ID: 26746849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
